May 13, 2021 08:10 AM EDT

Covid-19 manufacturing roundup: Emergent starts clean-up effort after disastrous Form 483; Eli Lilly expands licenses for Indian partners

Josh Sullivan

After botching millions of doses of a Covid-19 vaccine, being overtaken by the FDA and shaking up its leadership team, Emergent has completed a comprehensive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 manufacturing roundup: Emergent starts clean-up effort after disastrous Form 483; Eli Lilly expands licenses for Indian partners

Josh Sullivan

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Covid-19 man­u­fac­tur­ing roundup: Emer­gent starts clean-up ef­fort af­ter dis­as­trous Form 483; Eli Lil­ly ex­pands li­cens­es for In­di­an part­ners

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Covid-19 manufacturing roundup: Emergent starts clean-up effort after disastrous Form 483; Eli Lilly expands licenses for Indian partners